Bigtincan

Belkins
Bigtincan (ASX:BTH) helps sales and service teams increase win rates and customer satisfaction. The company’s mobile, AI-powered sales enablement automation platform features the industry’s premier user experience that empowers reps to more effectively engage with customers and prospects and encourages team-wide adoption. In addition to seven of the Fortune 10 companies, leading brands including AT&T, ThermoFisher, Merck, ANZ Bank and others rely on Bigtincan to enhance sales productivity at every customer interaction. With global sales and marketing headquartered in Boston, Bigtincan also has offices across EMEA, Australia and Asia. To discover more about how your organization can benefit from the Bigtincan Hub platform.

C-Suite On Deck

Patrick Welch, President and CMO at Bigtincan is a top performing senior executive with 22 years’ experience managing, bringing to market and selling innovative software management solutions to various high value market segments.

Patrick is an inspirational executive...

Events

Related News

INDUSTRY OUTLOOK

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

news image

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More

BAY AREA BIOTECH INCUBATOR OPENS EXTENSIVE NEW LAB FACILITY, PAVING WAY FOR ENTREPRENEURS AND THEIR INNOVATION

MBC BioLabs | May 11, 2020

news image

Innovation and discovery just got easier for life science entrepreneurs as MBC BioLabs announces the opening of a 30,000 square foot building of incubator lab space in San Carlos, Calif.Built specifically as a life-science incubator space over the past 18 months, the new facility brings cutting-edge lab equipment, infrastructure and services to innovators and entrepreneurs so they can begin their discovery work virtually immediately. This is MBC BioLabs' third campus and its seco...

Read More

CELL AND GENE THERAPY

AMYRIS PARTNERS WITH INSCRIPTA TO ENHANCE DEVELOPMENT OF SUSTAINABLE INGREDIENTS USING THE ONYX™ GENOME ENGINEERING PLATFORM

Amyris | October 06, 2021

news image

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' prod...

Read More

KYTOPEN PARTNERS WITH CAMBRIDGE CONSULTANTS ON FLOWFECT

Genetic Engineering and Biotechnology News | January 28, 2020

news image

MIT spin-out company Kytopen signed a deal with Cambridge Consultants to co-develop the FlowfectTM system, a scalable process that reportedly yields billions of engineered cells in minutes. The product will streamline the engineering of a wide array of human and human-derived cells for use in next-generation cell therapies, with the goal of expanding access to new medicines, says Paulo Garcia, CEO and co-founder of Kytopen....

Read More

INDUSTRY OUTLOOK

Xalud Therapeutics | August 25, 2021

news image

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More

MBC BioLabs | May 11, 2020

news image

BAY AREA BIOTECH INCUBATOR OPENS EXTENSIVE NEW LAB FACILITY, PAVING WAY FOR ENTREPRENEURS AND THEIR INNOVATION

Innovation and discovery just got easier for life science entrepreneurs as MBC BioLabs announces the opening of a 30,000 square foot building of incubator lab space in San Carlos, Calif.Built specifically as a life-science incubator space over the past 18 months, the new facility brings cutting-edge lab equipment, infrastructure and services to innovators and entrepreneurs so they can begin their discovery work virtually immediately. This is MBC BioLabs' third campus and its seco...

Read More

CELL AND GENE THERAPY

Amyris | October 06, 2021

news image

AMYRIS PARTNERS WITH INSCRIPTA TO ENHANCE DEVELOPMENT OF SUSTAINABLE INGREDIENTS USING THE ONYX™ GENOME ENGINEERING PLATFORM

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' prod...

Read More

Genetic Engineering and Biotechnology News | January 28, 2020

news image

KYTOPEN PARTNERS WITH CAMBRIDGE CONSULTANTS ON FLOWFECT

MIT spin-out company Kytopen signed a deal with Cambridge Consultants to co-develop the FlowfectTM system, a scalable process that reportedly yields billions of engineered cells in minutes. The product will streamline the engineering of a wide array of human and human-derived cells for use in next-generation cell therapies, with the goal of expanding access to new medicines, says Paulo Garcia, CEO and co-founder of Kytopen....

Read More